Published in Inflamm Res on November 10, 2009
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 1.22
Effect of dentin etching and chlorhexidine application on metalloproteinase-mediated collagen degradation. Eur J Oral Sci (2011) 1.05
Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.05
Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med (2010) 0.96
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett (2011) 0.94
Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity. Ther Adv Chronic Dis (2012) 0.88
Zinc reduces collagen degradation in demineralized human dentin explants. J Dent (2010) 0.87
Coptisine Prevented IL-β-Induced Expression of Inflammatory Mediators in Chondrocytes. Inflammation (2016) 0.84
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. J Med Chem (2014) 0.82
Small molecule inhibitors of WNT/β-catenin signaling block IL-1β- and TNFα-induced cartilage degradation. Arthritis Res Ther (2013) 0.80
MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes. Am J Transl Res (2015) 0.79
Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins. J Biol Chem (2012) 0.79
Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain. PLoS One (2010) 0.78
New strategies for targeting matrix metalloproteinases. Matrix Biol (2015) 0.77
Scarless wound healing. J Am Col Certif Wound Spec (2010) 0.76
Profiling the secretion of soluble mediators by end stage osteoarthritis synovial tissue explants reveals a reduced responsiveness to an inflammatory trigger. PLoS One (2013) 0.75
Metalloproteinase binding proteins: WO2009097397. Expert Opin Ther Pat (2010) 0.75
In vivo evaluation of Mg-6Zn and titanium alloys on collagen metabolism in the healing of intestinal anastomosis. Sci Rep (2017) 0.75
CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights (2013) 0.75
Potential of Pseudoshikonin I Isolated from Lithospermi Radix as Inhibitors of MMPs in IL-1β-Induced SW1353 Cells. Int J Mol Sci (2016) 0.75
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes. J Med Chem (2015) 0.75
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest (1996) 4.10
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum (2005) 3.31
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res (2001) 3.24
Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest (2001) 2.90
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum (2002) 2.66
Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum (2005) 2.37
Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des (2007) 2.26
Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation (2005) 2.01
Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem (2003) 1.93
Matrix metalloproteinases in arthritic disease. Arthritis Res (2002) 1.75
Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol (2001) 1.69
Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum (2000) 1.57
The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum (2002) 1.52
Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum (2000) 1.47
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum (2002) 1.38
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem (2007) 1.37
Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest (2007) 1.32
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum (2003) 1.26
Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene (2004) 1.22
An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta (2000) 1.19
The regulation of MMPs and TIMPs in cartilage turnover. Ann N Y Acad Sci (1999) 1.13
Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets (2003) 1.11
Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets (2007) 1.06
Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther (2006) 1.01
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis (2009) 1.00
The expression, refolding, and purification of the catalytic domain of human collagenase-3 (MMP-13). Protein Expr Purif (1998) 0.96
Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor. Ann N Y Acad Sci (1999) 0.78
Mass spectrometric analysis of surfactant metabolism in human volunteers using deuteriated choline. Am J Respir Crit Care Med (2004) 1.51
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum (2009) 1.38
Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci (2005) 1.06
Matrix metalloprotease inhibitors suppress initiation and progression of chondrogenic differentiation of mesenchymal stromal cells in vitro. Stem Cells Dev (2009) 0.86
Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries. Proc Natl Acad Sci U S A (2002) 0.85
A high-throughput microtiter plate-based screening method for the detection of full-length recombinant proteins. Protein Expr Purif (2008) 0.76
Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. J Med Chem (2003) 0.76